An Open-Label Phase 1b Study of the Safety and Tolerability of Atezolizumab (anti-PDL1 antibody) Administered in Combination with Gemcitabine and nab-Paclitaxel in Subjects with Metastatic Pancreatic Cancer
An Open-Label Phase 1b Study of the Safety and Tolerability of Atezolizumab (anti-PDL1 antibody) Administered in Combination with Gemcitabine and nab-Paclitaxel in Subjects with Metastatic Pancreatic Cancer
Phase:
I
An Open-Label Phase 1b Study of the Safety and Tolerability of Atezolizumab (anti-PDL1 antibody) Administered in Combination with Gemcitabine and nab-Paclitaxel in Subjects with Metastatic Pancreatic Cancer
Clinical Setting
First line treatment of metastatic pancreatic cancer
Study Description
This study is based on the hypothesis that chemotherapy will expose the tumor and allow for more effective killing of cancer cells by the immune system.
This study is open to patients who are physically well enough to perform self-care, ambulatory, and able to perform light duties.
